Evidence-based health, wellness, and longevity content from Dr. Tom Biernacki.
Myricetin activates AMPK and reduces glycation-induced oxidative stress in peripheral nerves. Dr. Tom reviews the preclinical evidence for this flavonoid in diabetic neuropathy and its protocol relevance.
60–70 million Americans have digestive disorders — most are treated with antacids that worsen the underlying cause. Dr. Tom’s functional GI protocol covers SIBO testing, H. pylori eradication, and gut repair.
Kaempferol modulates TRPV1 channels and reduces nerve growth factor-induced pain sensitization in diabetic neuropathy models. Dr. Tom reviews its anti-nociceptive and neuroprotective evidence.
Normal TSH doesn’t rule out Hashimoto’s. Dr. Tom explains the T3/T4 conversion problem, reverse T3 dominance, TPO antibodies, and the functional medicine approach to thyroid autoimmunity.
Naringenin reduces sorbitol accumulation and protein kinase C activation in diabetic peripheral nerves. Dr. Tom reviews its unique mechanisms among citrus flavanones and how it differs from hesperidin.
Neuroinflammation begins 20 years before Alzheimer’s symptoms. Dr. Tom explains BDNF decline, microglial activation, the APOE4 risk variant, and the lifestyle interventions that measurably protect cognitive function.
Skin conditions like acne, eczema, and rosacea reflect gut dysbiosis — not just topical issues. Dr. Tom explains the gut-skin axis, the microbiome-immune link, and the inside-out treatment approach.
Fisetin has only 10% oral bioavailability — formulation matters. Dr. Tom reviews liposomal and fat-soluble delivery strategies, the senolytic dosing protocol, and fisetin’s neuroprotective mechanisms.
88% of Americans are metabolically unhealthy. Dr. Tom explains the HOMA-IR calculation, the fasting insulin threshold, and the time-restricted eating and exercise protocols that reverse insulin resistance.
Pterostilbene crosses the blood-brain barrier 4x more effectively than resveratrol. Dr. Tom compares these stilbene cousins and reviews pterostilbene’s evidence specifically for diabetic peripheral neuropathy.